The Children's Oncology Group (COG) Statistics and Data Center (SDC), collaborates with the COG membership to design, conduct analyze and report the results of clinical trials of the treatment of childhood cancers and associated, laboratory-based, companion studies of the biology of these malignancies. Specifically, COG SDC personnel: Participate in the setting and evaluation of COG research priorities; collaborate in the development of study concepts and protocols. In particular, members of the SDC develop the study's statistical considerations; collaborate in the development and implementation of the study's case- report forms for the Group's clinical data management system; monitor study enrollment and the quality and completeness of study data submission; produce interim reports on study conduct and adverse event experience for the Group membership and protocol-specified interim analyses of study outcomes for the Group's Data and Safety Monitoring Committees; produce final reports of the study results for the Group membership; collaborate with laboratories to link specimen data and high dimensional genomics data with COG clinical and outcome data and to produce analyses of these data for publication; produce Technical Reports, detailing analyses performed for Group abstracts and manuscripts; conduct database and methodological research of relevance to the Group's research; perform CDUS and results reporting; monitor the performance of COG member institutions, producing reports for the Group's Institutional Performance monitoring Committee; provide data derived from COG studies to investigators external to the SDC in accordance with the policies and procedures of the Group; participate in National Clinical Trials Network initiatives and CTEP committees as appropriate.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Florida
Biostatistics & Other Math Sci
Schools of Medicine
United States
Zip Code
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Teot, Lisa A; Schneider, Michaela; Thorner, Aaron R et al. (2018) Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer 124:1973-1981
Poynter, Jenny N; Richardson, Michaela; Roesler, Michelle et al. (2018) Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group. Br J Cancer 118:121-126
Zheng, Daniel J; Lu, Xiaomin; Schore, Reuven J et al. (2018) Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer 124:571-579
Untanu, Ramona Vesna; Back, Jason; Appel, Burton et al. (2018) Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Henderson, Tara O; Parsons, Susan K; Wroblewski, Kristen E et al. (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136-144
de Alarcon, Pedro A; Matthay, Katherine K; London, Wendy B et al. (2018) Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health 2:25-34
Dicken, Bryan J; Billmire, Deborah F; Krailo, Mark et al. (2018) Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatr Blood Cancer 65:
Walterhouse, David O; Barkauskas, Donald A; Hall, David et al. (2018) Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. J Clin Oncol :JCO2018789388
Cole, Peter D; McCarten, Kathleen M; Pei, Qinglin et al. (2018) Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol 19:1229-1238

Showing the most recent 10 out of 317 publications